• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

斑秃患者报告的决定斑秃严重程度的因素调查:一项全国性多中心研究

Survey on Alopecia Areata Patients' Reported Factors that Determine Severity of Alopecia Areata: A Nationwide Multicenter Study.

作者信息

Kim Jung Eun, Lee Subin, Kang Hoon, Lee Young, Kim Do-Young, Park Hyunsun, Shin Hyun-Tae, Jang Yong Hyun, Shin Kihyuk, Lee Ji Hae, Choi Jee Woong, Park Byung Choel, Kim Beom Joon, Seo Soo Hong, Won Chong Hyun, Park Jin, Kim Min Sung, Kim Sang Seok, Lew Bark-Lynn, Huh Chang-Hun, Kwon Ohsang, Lee Yang Won, Kim Moon-Bum

机构信息

Department of Dermatology, The Catholic University of Korea, College of Medicine, Seoul, Korea.

Department of Dermatology, Chungnam National University School of Medicine, Daejeon, Korea.

出版信息

Ann Dermatol. 2024 Dec;36(6):376-383. doi: 10.5021/ad.24.033.

DOI:10.5021/ad.24.033
PMID:39623614
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11621644/
Abstract

BACKGROUND

Alopecia areata (AA) is characterized by hair loss on the scalp and body, significantly impacting patients' quality of life based on its severity.

OBJECTIVE

This study aims to identify crucial factors influencing the perception of severe AA from the patients' viewpoint.

METHODS

A web-based survey was conducted among AA patients attending dermatology departments at 21 university hospitals in Korea. The survey comprised 17 criteria, exploring both clinical characteristics of AA patients and subjective determinants of disease severity.

RESULTS

A total of 791 AA patients and their caregivers participated in the survey. Approximately 30% of respondents developed AA during childhood, with 43.5% experiencing chronic courses lasting over 3 years. Half of the participants exhibited more than 20% scalp hair loss, and 42% reported additional hair loss on other body parts, such as eyelashes and nose hair. Most respondents agreed that patients with ≥20% scalp hair loss should be categorized as having severe AA. They also identified longer disease duration, involvement of non-scalp body hair, treatment refractoriness, and social or mental impairment requiring medical intervention as factors indicating increased disease severity.

CONCLUSION

This survey underscores the significant impact of AA on patients' quality of life and highlights existing unmet needs in current treatment modalities.

摘要

背景

斑秃(AA)的特征是头皮和身体毛发脱落,根据其严重程度对患者的生活质量有显著影响。

目的

本研究旨在从患者的角度确定影响重度斑秃认知的关键因素。

方法

在韩国21所大学医院皮肤科就诊的斑秃患者中进行了一项基于网络的调查。该调查包括17项标准,探讨了斑秃患者的临床特征和疾病严重程度的主观决定因素。

结果

共有791名斑秃患者及其护理人员参与了调查。约30%的受访者在儿童时期患上斑秃,43.5%经历了持续超过3年的慢性病程。一半的参与者头皮脱发超过20%,42%报告身体其他部位如睫毛和鼻毛也有额外脱发。大多数受访者同意,头皮脱发≥20%的患者应被归类为重度斑秃。他们还确定病程较长、非头皮身体毛发受累、治疗难治性以及需要医疗干预的社会或心理障碍是疾病严重程度增加的指标。

结论

本次调查强调了斑秃对患者生活质量的重大影响,并突出了当前治疗方式中存在的未满足需求。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a535/11621644/eb4c3400295c/ad-36-376-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a535/11621644/50cf214bfdd2/ad-36-376-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a535/11621644/111aeb267106/ad-36-376-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a535/11621644/d0f0a7f7d06b/ad-36-376-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a535/11621644/830145fb3165/ad-36-376-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a535/11621644/eb4c3400295c/ad-36-376-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a535/11621644/50cf214bfdd2/ad-36-376-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a535/11621644/111aeb267106/ad-36-376-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a535/11621644/d0f0a7f7d06b/ad-36-376-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a535/11621644/830145fb3165/ad-36-376-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a535/11621644/eb4c3400295c/ad-36-376-g005.jpg

相似文献

1
Survey on Alopecia Areata Patients' Reported Factors that Determine Severity of Alopecia Areata: A Nationwide Multicenter Study.斑秃患者报告的决定斑秃严重程度的因素调查:一项全国性多中心研究
Ann Dermatol. 2024 Dec;36(6):376-383. doi: 10.5021/ad.24.033.
2
Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey.患者报告的重度斑秃负担:多国斑秃未满足需求调查的初步结果
Clin Cosmet Investig Dermatol. 2024 Mar 29;17:751-761. doi: 10.2147/CCID.S445646. eCollection 2024.
3
The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials.斑秃研究者全球评估量表:一种用于评估临床试验中具有临床意义的成功的测量方法。
Br J Dermatol. 2020 Oct;183(4):702-709. doi: 10.1111/bjd.18883. Epub 2020 Apr 3.
4
The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity.斑秃严重度和发病率指数(ASAMI)研究:全球专家共识关于斑秃严重度决定因素的结果。
JAMA Dermatol. 2024 Mar 1;160(3):341-350. doi: 10.1001/jamadermatol.2023.5869.
5
Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan.日本皮肤科医生和患者对斑秃治疗成功率的看法及临床疗效评估
Dermatol Ther (Heidelb). 2021 Apr;11(2):433-447. doi: 10.1007/s13555-020-00477-6. Epub 2021 Jan 10.
6
The Relationship Between Patient-Reported Severity of Hair Loss and Health-Related Quality of Life and Treatment Patterns Among Patients with Alopecia Areata.斑秃患者报告的脱发严重程度与健康相关生活质量及治疗模式之间的关系
Dermatol Ther (Heidelb). 2022 Apr;12(4):989-997. doi: 10.1007/s13555-022-00702-4. Epub 2022 Mar 29.
7
Alopecia areata severity index (AASI): A reliable scoring system to assess the severity of alopecia areata on face and scalp-a pilot study.斑秃严重程度指数 (AASI):一种评估面部和头皮斑秃严重程度的可靠评分系统——一项初步研究。
J Cosmet Dermatol. 2021 Aug;20(8):2565-2570. doi: 10.1111/jocd.14289. Epub 2021 Jun 26.
8
Childhood Alopecia Areata: An Overview of Treatment and Recent Patents.儿童斑秃:治疗概述及近期专利。
Recent Pat Inflamm Allergy Drug Discov. 2020;14(2):117-132. doi: 10.2174/1872213X14999200728145822.
9
Evaluation of SALT score severity in correlation with trichoscopic findings in alopecia areata: a study of 303 patients.斑秃中SALT评分严重程度与毛发镜检查结果的相关性评估:一项对303例患者的研究
Arch Dermatol Res. 2025 Mar 7;317(1):523. doi: 10.1007/s00403-025-04026-z.
10
Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata.口服酪氨酸激酶3/肝细胞癌中表达的酪氨酸激酶家族激酶抑制剂芦可替尼24个月的疗效和安全性:斑秃的ALLEGRO IIb/III期和长期III期临床研究的综合分析
Br J Dermatol. 2025 Jan 24;192(2):215-227. doi: 10.1093/bjd/ljae365.

本文引用的文献

1
Eyelash length attractiveness across ethnicities.不同种族的睫毛长度吸引力。
Sci Rep. 2023 Sep 8;13(1):14849. doi: 10.1038/s41598-023-41739-5.
2
Guidelines for the Management of Patients with Alopecia Areata in Korea: Part I Topical and Device-based Treatment.韩国斑秃患者管理指南:第一部分 局部及基于器械的治疗
Ann Dermatol. 2023 Jun;35(3):190-204. doi: 10.5021/ad.22.168.
3
Impact and Management of Loss of Eyebrows and Eyelashes.眉毛和睫毛缺失的影响与处理
Dermatol Ther (Heidelb). 2023 Jun;13(6):1243-1253. doi: 10.1007/s13555-023-00925-z. Epub 2023 May 15.
4
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.利特昔替尼治疗成人和青少年斑秃的疗效和安全性:一项随机、双盲、多中心、2b-3 期临床试验。
Lancet. 2023 May 6;401(10387):1518-1529. doi: 10.1016/S0140-6736(23)00222-2. Epub 2023 Apr 14.
5
Increased Risk of Suicide Attempt in Patients with Alopecia Areata: A Nationwide Population-Based Cohort Study.斑秃患者自杀未遂风险增加:一项全国范围内基于人群的队列研究。
Dermatology. 2023;239(5):712-719. doi: 10.1159/000530076. Epub 2023 Mar 15.
6
Anxiety, depression, and quality of life in children and adults with alopecia areata: A systematic review and meta-analysis.斑秃儿童和成人的焦虑、抑郁及生活质量:一项系统评价与荟萃分析。
Front Med (Lausanne). 2022 Nov 29;9:1054898. doi: 10.3389/fmed.2022.1054898. eCollection 2022.
7
The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies.JAK抑制剂治疗斑秃的疗效与安全性:前瞻性研究的系统评价与荟萃分析
Front Pharmacol. 2022 Aug 24;13:950450. doi: 10.3389/fphar.2022.950450. eCollection 2022.
8
Two Phase 3 Trials of Baricitinib for Alopecia Areata.两项关于巴瑞替尼治疗斑秃的3期试验。
N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26.
9
Development and validation of the Brigham Eyelash Tool for Alopecia (BELA): A measure of eyelash alopecia areata.用于斑秃的布莱根睫毛工具(BELA)的开发与验证:一种斑秃性睫毛脱落的测量方法。
J Am Acad Dermatol. 2021 Jul;85(1):271-272. doi: 10.1016/j.jaad.2020.06.1034. Epub 2021 Mar 16.
10
Consensus on the treatment of alopecia areata - Brazilian Society of Dermatology.斑秃治疗共识 - 巴西皮肤病学会
An Bras Dermatol. 2020 Nov-Dec;95 Suppl 1(Suppl 1):39-52. doi: 10.1016/j.abd.2020.05.006. Epub 2020 Oct 8.